Your browser doesn't support javascript.
loading
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski, Grzegorz S; Yoon, Dok Hyun; Mondello, Patrizia; Joffe, Erel; Peters, Anthea; Fleury, Isabelle; Greil, Richard; Ku, Matthew; Marks, Reinhard; Kim, Kibum; Zinzani, Pier Luigi; Trotman, Judith; Sabatelli, Lorenzo; Waltl, Eva E; Winderlich, Mark; Sporchia, Andrea; Kurukulasuriya, Nuwan C; Cordoba, Raul; Hess, Georg; Salles, Gilles.
Afiliação
  • Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Nowakowski.Grzegorz@mayo.edu.
  • Yoon DH; Department of Oncology, Asan Medical Center, Songpa-gu, Seoul, South Korea.
  • Mondello P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Joffe E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Peters A; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
  • Fleury I; Maisonneuve-Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Canada.
  • Greil R; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT, and Cancer Cluster Salzburg, Salzburg, Austria.
  • Ku M; Department of Haematology, St Vincent's Hospital and University of Melbourne, Melbourne, Victoria, Australia.
  • Marks R; University Hospital Freiburg Internal Medicine I, Freiburg im Breisgau, Germany.
  • Kim K; University of Utah, Salt Lake City, UT, USA.
  • Zinzani PL; University of Illinois at Chicago, Chicago, IL, USA.
  • Trotman J; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Sabatelli L; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.
  • Waltl EE; Haematology Department, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
  • Winderlich M; Incyte Biosciences International Sàrl, Morges, Switzerland.
  • Sporchia A; MorphoSys AG, Planegg, Germany.
  • Kurukulasuriya NC; MorphoSys AG, Planegg, Germany.
  • Cordoba R; MorphoSys AG, Planegg, Germany.
  • Hess G; MorphoSys AG, Boston, MA, USA.
  • Salles G; Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IISFJD, Madrid, Spain.
Ann Hematol ; 102(7): 1773-1787, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37171597
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma Difuso de Grandes Células B / Receptores de Antígenos Quiméricos Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma Difuso de Grandes Células B / Receptores de Antígenos Quiméricos Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos